D. Hanahan, Hallmarks of cancer: the next generation, Cell. Elsevier Inc, vol.144, pp.646-74, 2011.

A. Banerji, U. Workman, and P. , Combinatorial drug therapy for cancer in the post-genomic era, Nat Biotechnol. Nature Publishing Group, vol.30, pp.679-92, 2012.

P. Creixell, E. M. Schoof, J. T. Erler, and R. Linding, Navigating cancer network attractors for tumor-specific therapy, Nat Biotechnol, vol.30, p.22965061, 2012.

A. S. Crystal, A. T. Shaw, L. Sequist, L. Friboulet, M. J. Niederst et al., Patient-derived models of acquired resistance can identify effective drug combinations for cancer, Science, p.25394791, 2014.

. Borisy, P. J. Elliott, N. W. Hurst, M. S. Lee, J. Lehar et al., Systematic discovery of multicomponent therapeutics, Proc Natl Acad Sci U S A, vol.100, pp.7977-82, 2003.

B. Klinger, A. Sieber, R. Fritsche-guenther, F. Witzel, L. Berry et al., Network quantification of EGFR signaling unveils potential for targeted combination therapy, Mol Syst Biol, vol.9, p.23752269, 2013.

M. Bansal, J. Yang, C. Karan, M. P. Menden, J. C. Costello et al., A community computational challenge to predict the activity of pairs of compounds, Nat Biotechnol. Nature Publishing Group, 2014.

M. Griner-l-a, R. Guha, P. Shinn, R. M. Young, J. M. Keller et al., High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells, Proc Natl Acad Sci U S A, vol.111, p.24469833, 2014.

M. L. Miller, E. J. Molinelli, J. S. Nair, T. Sheikh, R. Samy et al., Drug Synergy Screen and Network Modeling in Dedifferentiated Liposarcoma Identifies CDK4 and IGF1R as Synergistic Drug Targets, Sci Signal, vol.6, p.24065146, 2013.

I. Albert, J. Thakar, S. Li, R. Zhang, and R. Albert, Boolean network simulations for life scientists, Source Code Biol Med, vol.3, p.16, 2008.

O. Sahin, H. Fröhlich, C. Löbke, U. Korf, S. Burmester et al., Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance, BMC Syst Biol, vol.3, p.1, 2009.

L. Calzone, L. Tournier, S. Fourquet, D. Thieffry, B. Zhivotovsky et al., Mathematical modelling of cell-fate decision in response to death receptor engagement, PLoS Comput Biol, vol.6, p.20221256, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00704979

R. Wang, A. Saadatpour, and R. Albert, Boolean modeling in systems biology: an overview of methodology and applications, Phys Biol, vol.9, p.55001, 2012.

D. Bérenguier, C. Chaouiya, P. T. Monteiro, A. Naldi, R. E. Thieffry et al., Dynamical modeling and analysis of large cellular regulatory networks, Chaos, vol.23, p.25114, 2013.

L. Novère and N. , Quantitative and logic modelling of molecular and gene networks, Nat Rev Genet. Nature Publishing Group, vol.16, pp.146-58, 2015.

R. Zhang, M. V. Shah, J. Yang, S. B. Nyland, X. Liu et al., Network model of survival signaling in large granular lymphocyte leukemia, Proc Natl Acad Sci U S A, vol.105, pp.16308-16313, 2008.

R. Schlatter, K. Schmich, A. Vizcarra, I. Scheurich, P. Sauter et al., ON/OFF and beyond-a boolean model of apoptosis, PLoS Comput Biol, vol.5, p.1000595, 2009.
DOI : 10.1371/journal.pcbi.1000595
URL : https://doi.org/10.1371/journal.pcbi.1000595

A. Saadatpour, R. Wang, A. Liao, X. Liu, T. P. Loughran et al., Dynamical and Structural Analysis of a T Cell Survival Network Identifies Novel Candidate Therapeutic Targets for Large Granular Lymphocyte Leukemia, PLoS Computational Biology, vol.7, 2011.

R. Schlatter, K. Schmich, A. Lutz, J. Trefzger, O. Sawodny et al., Modeling the TNF?-induced apoptosis pathway in hepatocytes, PLoS One, vol.6, p.21533085, 2011.
DOI : 10.1371/journal.pone.0018646
URL : https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0018646&type=printable

R. Poltz and M. Naumann, Dynamics of p53 and NF-?B regulation in response to DNA damage and identification of target proteins suitable for therapeutic intervention, BMC Systems Biology, vol.6, p.125, 2012.

L. Grieco, L. Calzone, I. Bernard-pierrot, F. Radvanyi, B. Kahn-perlès et al., Integrative Modelling of the Influence of MAPK Network on Cancer Cell Fate Decision, PLoS Computational Biology, vol.9, p.1003286, 2013.

H. F. Fumiã and M. L. Martins, Boolean network model for cancer pathways: predicting carcinogenesis and targeted therapy outcomes, PLoS One, vol.8, p.23922675, 2013.

S. Von-der-heyde, C. Bender, F. Henjes, J. Sonntag, U. Korf et al., Boolean ErbB network reconstructions and perturbation simulations reveal individual drug response in different breast cancer cell lines, BMC Syst Biol, vol.8, p.24970389, 2014.

S. A. Forbes, N. Bindal, S. Bamford, C. Cole, C. Y. Kok et al., COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer, Nucleic Acids Res, vol.39, p.20952405, 2011.

J. Barretina, G. Caponigro, N. Stransky, K. Venkatesan, and S. Kim, The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity, Nature, vol.483, p.22460905, 2012.
DOI : 10.1038/nature11003
URL : http://europepmc.org/articles/pmc3320027?pdf=render

A. Naldi, R. E. Thieffry, D. Chaouiya, and C. , Dynamically consistent reduction of logical regulatory graphs, Theoretical Computer Science. Elsevier B.V, vol.412, pp.2207-2218, 2011.
DOI : 10.1016/j.tcs.2010.10.021
URL : https://hal.archives-ouvertes.fr/hal-01284743

W. Yang, J. Soares, P. Greninger, E. J. Edelman, H. Lightfoot et al., Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells, Nucleic Acids Res, vol.41, pp.955-61, 2013.

S. Loewe, The problem of synergism and antagonism of combined drugs, Arzneimittelforschung, vol.3, p.13081480, 1953.

T. Chou and P. Talalay, Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors, Adv Enzyme Regul, vol.22, p.6382953, 1984.

J. G. Shelton, L. S. Steelman, J. T. Lee, S. L. Knapp, W. L. Blalock et al., Effects of the RAF/MEK/ ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells, Oncogene, vol.22, pp.2478-92, 2003.

S. Iadevaia, Y. Lu, F. C. Morales, G. B. Mills, and P. T. Ram, Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis, Cancer Res, vol.70, pp.6704-6718, 2010.
DOI : 10.1158/0008-5472.can-10-0460
URL : http://cancerres.aacrjournals.org/content/70/17/6704.full.pdf

J. Meng, B. Dai, B. Fang, B. N. Bekele, W. G. Bornmann et al., Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo, PLoS One, vol.5, 2010.

G. Migliardi, F. Sassi, D. Torti, F. Galimi, E. R. Zanella et al., Inhibition of MEK and PI3K/ mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas, Clin Cancer Res, vol.18, pp.2515-2540, 2012.

E. Kandil, K. Tsumagari, J. Ma, A. Elmageed, Z. Y. Li et al., Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways, J Surg Res. Elsevier Ltd, vol.184, p.23602735, 2013.

A. Eijkelenboom and B. Burgering, FOXOs: signalling integrators for homeostasis maintenance, Nat Rev Mol Cell Biol, vol.14, pp.83-97, 2013.

S. Shankar, Q. Chen, and R. K. Srivastava, Inhibition of PI3K/AKT and MEK/ERK pathways act synergistically to enhance antiangiogenic effects of EGCG through activation of FOXO transcription factor, J Mol Signal, vol.3, p.7, 2008.

J. Arthur and S. C. Ley, Mitogen-activated protein kinases in innate immunity, Nat Rev Immunol. Nature Publishing Group, vol.13, p.23954936, 2013.

S. Kim, Y. Kim, J. Lee, and J. Chung, Regulation of FOXO1 by TAK1-Nemo-like kinase pathway, J Biol Chem, vol.285, pp.8122-8131, 2010.

E. Lam, J. J. Brosens, A. R. Gomes, and C. Koo, Forkhead box proteins: tuning forks for transcriptional harmony, Nat Rev Cancer. Nature Publishing Group, vol.13, p.23792361, 2013.

J. Lehár, A. S. Krueger, W. Avery, A. M. Heilbut, L. M. Johansen et al., Synergistic drug combinations tend to improve therapeutically relevant selectivity, Nat Biotechnol, vol.27, p.19581876, 2009.

I. Bozic, J. G. Reiter, B. Allen, T. Antal, K. Chatterjee et al., Evolutionary dynamics of cancer in response to targeted combination therapy, eLife, vol.2, p.747, 2013.

S. Kopetz, R. Lemos, and G. Powis, The promise of patient-derived xenografts: the best laid plans of mice and men, Clin Cancer Res, vol.18, pp.5160-5162, 2012.

J. L. Wilding and W. F. Bodmer, Cancer cell lines for drug discovery and development, Cancer Research, vol.74, pp.2377-2384, 2014.

E. Garralda, K. Paz, P. P. López-casas, S. Jones, A. Katz et al., Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment, Clin Cancer Res, vol.20, pp.2476-84, 2014.

G. Ciriello, M. L. Miller, B. A. Aksoy, Y. Senbabaoglu, N. Schultz et al., Emerging landscape of oncogenic signatures across human cancers, Nat Genet. Nature Publishing Group, vol.45, p.24071851, 2013.

A. J. Bass, V. Thorsson, I. Shmulevich, S. M. Reynolds, M. Miller et al., Comprehensive molecular characterization of gastric adenocarcinoma, Nature. Nature Publishing Group, vol.513, pp.202-209, 2014.

M. J. Lee, A. S. Ye, A. K. Gardino, A. M. Heijink, P. K. Sorger et al., Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks, Cell. Elsevier Inc, vol.149, p.22579283, 2012.

J. R. Pritchard, P. M. Bruno, L. A. Gilbert, K. L. Capron, D. A. Lauffenburger et al., Defining principles of combination drug mechanisms of action, Proc Natl Acad Sci U S A, vol.110, p.23251029, 2013.

R. Zielinski, P. F. Przytycki, J. Zheng, D. Zhang, T. M. Przytycka et al., The crosstalk between EGF, IGF, and Insulin cell signaling pathways-computational and experimental analysis, BMC Syst Biol. BioMed Central Ltd, vol.3, p.88, 2009.

A. L. Bauer, T. L. Jackson, Y. Jiang, and T. Rohlf, Receptor cross-talk in angiogenesis: mapping environmental cues to cell phenotype using a stochastic, Boolean signaling network model, J Theor Biol, vol.264, p.20307549, 2010.

A. Singh, J. M. Nascimento, S. Kowar, H. Busch, and M. Boerries, Boolean approach to signalling pathway modelling in HGF-induced keratinocyte migration, Bioinformatics, vol.28, pp.495-501, 2012.

S. Nelander, W. Wang, B. Nilsson, Q. She, C. Pratilas et al., Models from experiments: combinatorial drug perturbations of cancer cells, Mol Syst Biol, vol.4, p.18766176, 2008.

W. R. Greco, G. Bravo, and J. C. Parsons, The search for synergy: a critical review from a response surface perspective, Pharmacol Rev, vol.47, p.7568331, 1995.

D. M. Wittmann, J. Krumsiek, J. Saez-rodriguez, S. Klamt, and F. J. Theis, Transforming Boolean models to continuous models: methodology and application to T-cell receptor signaling, BMC Syst Biol, vol.3, p.98, 2009.

C. H. Ooi, T. Ivanova, J. Wu, M. Lee, I. B. Tan et al., Oncogenic pathway combinations predict clinical prognosis in gastric cancer, PLoS Genet, vol.5, p.1000676, 2009.

I. B. Tan, T. Ivanova, K. H. Lim, C. W. Ong, N. Deng et al., Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy, Gastroenterology, vol.141, p.21684283, 2011.

R. Wadhwa, S. Song, J. Lee, Y. Yao, and Q. Wei, Gastric cancer-molecular and clinical dimensions, Nat Rev Clin Oncol. Nature Publishing Group, vol.10, p.24061039, 2013.

M. Orditura, G. Galizia, V. Sforza, V. Gambardella, A. Fabozzi et al., Treatment of gastric cancer, World J Gastroenterol, vol.20, p.24587643, 2014.

, See for instance clinical trials NCT01347866, NCT01363232, NCT01337765 and NCT00996892

, See for instance clinical trials NCT01476137, NCT01138085, NCT01907815 and NCT01333475

R. Thomas, Regulatory networks seen as asynchronous automata: A logical description, Journal of Theoretical Biology, vol.153, pp.1-23, 1991.

H. Clevers and R. Nusse, Wnt/?-catenin signaling and disease, Cell, vol.149, p.22682243, 2012.

N. Carayol and C. Wang, IKKalpha stabilizes cytosolic beta-catenin by inhibiting both canonical and noncanonical degradation pathways, Cell Signal, vol.18, pp.1941-1947, 2006.

A. Oeckinghaus, M. S. Hayden, and S. Ghosh, Crosstalk in NF-?B signaling pathways, Nat Immunol, vol.12, pp.695-708, 2011.

H. Mita, M. Toyota, F. Aoki, H. Akashi, R. Maruyama et al., A novel method, digital genome scanning detects KRAS gene amplification in gastric cancers: involvement of overexpressed wild-type KRAS in downstream signaling and cancer cell growth, BMC Cancer, vol.9, p.198, 2009.

S. Asciutti, G. Akiri, L. Grumolato, and S. Vijayakumar, Diverse mechanisms of Wnt activation and effects of pathway inhibition on proliferation of human gastric carcinoma cells. Oncogene, vol.30, pp.956-66, 2011.

A. Naldi, D. Berenguier, A. Fauré, F. Lopez, D. Thieffry et al., Logical modelling of regulatory networks with GINsim 2.3, Biosystems, vol.97, pp.134-143, 2009.

T. Chou, Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies, Pharmacol Rev, vol.58, pp.621-81, 2006.